Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Allison Berger"'
Autor:
Xiaoguang Wang, Canping Chen, Dan Vuong, Sonia Rodriguez-Rodriguez, Vi Lam, Carly Roleder, Jing H. Wang, Swetha Kambhampati, Allison Berger, Nathan Pennock, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Tanya Siddiqi, Lili Wang, Zheng Xia, Alexey V. Danilov
Publikováno v:
Leukemia.
Neddylation is a sequential enzyme-based process which regulates the function of E3 Cullin-RING ligase (CRL) and thus degradation of substrate proteins. Here we show that CD8+ T cells are a direct target for therapeutically relevant anti-lymphoma act
Autor:
Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro, Dennis Huszar
Publikováno v:
Blood. 139(18)
Small ubiquitin-like modifier (SUMO) is a member of a ubiquitin-like protein superfamily. SUMOylation is a reversible posttranslational modification that has been implicated in the regulation of various cellular processes including inflammatory respo
Autor:
Maria Patra-Kneuer, Stefan Steidl, Akito Nakamura, Andrea Polzer, Stephen Grossman, Igor Proscurshim, Carmen Ginzel, Keli Song, Christina Heitmüller, Allison Berger
Publikováno v:
Blood. 138:2268-2268
Introduction TAK-981 is a first-in-class small molecule inhibitor of the SUMO activating enzyme currently in Phase I/II clinical trials. TAK-981 has been shown to increase NK cell activation and M1 macrophage polarization via upregulation of Type I i
Autor:
Lili Wang, Xiaoguang Wang, Tanya Siddiqi, Allison Berger, Alexey V. Danilov, Dan Vuong, Vi Lam, Olga V. Danilova, Tingting Liu
Publikováno v:
Blood. 138:2414-2414
Introduction: Immune checkpoint inhibitors have limited single agent activity in B-cell non-Hodgkin lymphoma (NHL). Hence, it is important to develop strategies which will thwart immune evasion in this disease. Neddylation is a sequential enzyme-base
Autor:
Shaji Kumar, Jeremy T. Larsen, Saulius Girnius, Rafat Abonour, Igor Proscurshim, Omar Nadeem, Akito Nakamura, Yuhong Zhang, Keli Song, Stefano R. Tarantolo, Vivek Roy, Meera Mohan, Moshe Yair Levy, Allison Berger, Deborah Berg, Cara A. Rosenbaum, Sagar Lonial, Ralph V. Boccia, Habte A. Yimer, Bo Chao, Christine K. Ward
Publikováno v:
Blood. 138:2742-2742
Background: SUMOylation, a post-translational modification analogous to ubiquitination, attaches a small, ubiquitin-like modifier (SUMO) to target proteins. SUMOylation plays a central role in the immune system by regulating type I interferon (IFN-I)
Autor:
Alejandro Gomez-Pinillos, Alonzo Martinez, Allison Berger, Amitkumar Mehta, Deborah Berg, Stephane Doucet, Paolo Caimi, Tycel Phillips, Lapo Alinari, Brenda W. Cooper, Bo Chao, Christine K. Ward, Igor Proscurshim, John Gibbs, Sarit Assouline, Alexey V. Danilov, Sharon Friedlander, Steven I. Park
Publikováno v:
Blood. 138:2488-2488
Background: TAK-981 is the first small-molecule inhibitor of SUMOylation to enter clinical trials. SUMOylation is a post-translational modification in which small ubiquitin-like modifier (SUMO) proteins are activated and covalently attached to substr
Autor:
Evan F. Lind, Vi Lam, Nathan D. Pennock, Scott R Best, Adam Kittai, Alexey V. Danilov, Nur Bruss, Allison Berger, Susan E. Murray, Tingting Liu, Olga V. Danilova
Publikováno v:
Leukemia
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcae410fe576a9e2b7a646012b4569dc
https://europepmc.org/articles/PMC8288064/
https://europepmc.org/articles/PMC8288064/
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no